Trials & Filings

Vaccitech Receives UK Grant to Support COVID-19 Tech Platform

Vaccitech's new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease.

By: Contract Pharma

Contract Pharma Staff

Vaccitech Ltd., a clinical stage biopharmaceutical company developing T cell induction products for infectious diseases and cancer, has received a UK Government grant to support research with its next-generation technology platform to protect against COVID-19. The grant is part of the UKRI-NIHR COVID-19 rapid response rolling call for proposals with potential to deliver public health impacts within 12 months. Preclinical data indicate Vaccitech’s new platform induces leading antibody an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters